



Wigs — MEDICAID/EPO Direct Pay (Bronze, Silver, Gold, Platinum)

Last Review Date: April 21, 2017

Number: MG.MM.DM.02dC7

Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definition

Wigs are considered to be a DME prosthetic appliance used to cover baldness.

Guideline

1. Medicaid/FHP members are eligible for coverage of wigs if the hair loss is secondary to any of the following conditions:
 - Burns with resulting permanent alopecia
 - Chemotherapy
 - Congenital baldness
 - Infections resulting in hair loss that are unresponsive to treatment
 - Lupus
 - Radiation therapy
 - Traumatic injury
 - Medical conditions that result in alopecia or alopecia totalis not listed above
2. Medicaid/FHP members are eligible for coverage of wig replacement if the wig becomes unusable or is lost.

The Plan will review all replacement requests on a case-by-case basis if the reason for the request is not cited above; however, the replacement will be denied if the rationale for the request falls within the Limitations/Exclusions section below.

There is no limitation on the number of *replacement wigs* that may be purchased *during the period of coverage*. However, it would be difficult to justify the need for more than one wig at a time.

Limitations/Exclusions

1. The member's treating physician must prescribe the wig
2. The Plan's reimbursement amount is the invoice cost to the provider plus 50%; if the price of the wig exceeds \$400, the provider would be required to explore a less costly alternative or the ordering physician would have to provide medical documentation substantiating that the wig was the only one available to fulfill the medical need
3. The Plan does not cover the initial purchase and/or replacement of a wig, as applicable, in the case of any of the following, as they are not the result of a medical disorder:
 - Damage incurred to the wig as a result of color dying
 - Damage incurred to the wig as a result of a permanent treatment application
 - Female pattern baldness
 - Male pattern baldness
 - Natural or premature aging

Applicable Procedure Codes

A9282	Wig, any type, each
-------	---------------------

Applicable Diagnosis Codes

B35.0	Tinea barbae and tinea capitis
L93.0	Discoid lupus erythematosus
L93.1	Subacute cutaneous lupus erythematosus
L93.2	Other local lupus erythematosus
M32.0	Drug-induced systemic lupus erythematosus
M32.10	Systemic lupus erythematosus, organ or system involvement unspecified
M32.19	Other organ or system involvement in systemic lupus erythematosus
M32.8	Other forms of systemic lupus erythematosus
M32.9	Systemic lupus erythematosus, unspecified
Q84.0	Congenital alopecia
Q84.1	Congenital morphological disturbances of hair, not elsewhere classified
Q84.2	Other congenital malformations of hair
T20.00xA	Burn of unspecified degree of head, face, and neck, unspecified site, initial encounter
T20.05xA	Burn of unspecified degree of scalp [any part], initial encounter
T20.10xA	Burn of first degree of head, face, and neck, unspecified site, initial encounter
T20.15xA	Burn of first degree of scalp [any part], initial encounter
T20.25xA	Burn of second degree of scalp [any part], initial encounter
T20.35xA	Burn of third degree of scalp [any part], initial encounter
T20.40xA	Corrosion of unspecified degree of head, face, and neck, unspecified site, initial encounter
T20.45xA	Corrosion of unspecified degree of scalp [any part], initial encounter
T20.50xA	Corrosion of first degree of head, face, and neck, unspecified site, initial encounter
T20.55xA	Corrosion of first degree of scalp [any part], initial encounter

T20.65xA	Corrosion of second degree of scalp [any part], initial encounter
T20.75xA	Corrosion of third degree of scalp [any part], initial encounter
T45.0X5A	Adverse effect of antiallergic and antiemetic drugs, initial encounter
T45.0X5S	Adverse effect of antiallergic and antiemetic drugs, sequela
T45.1X5A	Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter
T45.1X5S	Adverse effect of antineoplastic and immunosuppressive drugs, sequela
Z92.21	Personal history of antineoplastic chemotherapy
Z92.3	Personal history of irradiation